News

Both biologic-naïve and biologic-experience patients receiving guselkumab demonstrated significantly higher ACR20 when compared with ustekinumab.

Participants with RA had a 1.66-fold greater risk of depression compared to participants without RA, a new study found.

Test your knowledge of the ACR's guideline for the management of gout with this quiz!

The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.

A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.

After propensity score matching, patients with COVID-19 were at an increased risk for AIRD when compared with both uninfected controls and influenza-infected patients.

The decision was based on clinical studies demonstrating no clinically meaningful differences between the biosimilar and its reference product.

The overall effect of psychological interventions on patients with fibromyalgia was -0.31 for depressive symptoms and -0.15 for anxiety symptoms, which were deemed statistically significant.

The rheumatology month in review highlights cognitive dysfunction in patients with fibromyalgia, explores the impact of obesity on treatment response in rheumatoid arthritis, and evaluates work-related challenges faced by patients with psoriatic arthritis.

This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.

A progressive and significant increase in the frequency of strong opioid consumers was observed over a 12-year period, increasing from 5.8% to 12.8%.

At week 24, patients with moderate to severe PsA receiving risankizumab had a significantly higher ACR20 response rate when compared with placebo.

A study from Brigham and Women's Hospital has identified 6 blood-based biomarkers that may predict cardiovascular disease risk in rheumatoid arthritis patients.

No statistically significant differences in the odds of remission at ≤12 months were observed between patients receiving adalimumab compared with other biologics.

In an analysis of the DISCOVER-2 trial, guselkumab treatment reduced impairment in work productivity and improved general health status in PsA over 2 years.

Patients perceived WelTel as a beneficial tool for providing quality care across domains including efficiency, safety, and patient-centeredness.

Headache prevalence was significantly higher in the PsA and axSpA cohorts compared with healthy controls.

This announcement by UCB follows the results of four phase 3 studies on the use of bimekizumab for PsA, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

The presence of sinusitis is linked to a 40% heightened risk of a diagnosis of rheumatic disease, particularly in the 5 to 10 years before disease onset.

Patients with both psoriasis and psoriatic arthritis may be more likely to be tired based on symptom severity.

Most patients (82.6%) had minimal psoriasis skin involvement with a body surface area of < 3. However, 15.1% and 2.4% had a body surface area involvement of 3 – 10% and > 10, respectively.

Continuous improvement across all MDA domains was demonstrated over the 100-week timeframe, with approximately 70% of patients achieving near remission in swollen joint count, enthesitis, and the Psoriasis Area and Severity Index (PASI).

At the 6-month mark, between 73.2% to 78.6% of Canadian patients with psoriatic arthritis reported pain.

b/tsDMARD treatment led to a mean relative improvement of 41% for total work productivity in patients with psoriatic arthritis.

Findings provide insights into the current state of healthcare utilization for patients with gout living in South Korea.

Patients with gout and negative DECTs for monosodium urate crystal deposition exhibited milder disease and a lower comorbidity burden.

Among patients aged 40 – 49 years, asymptomatic hyperuricemia was linked to incident arthritis.

Often considered a cause of symptom onset in musculoskeletal conditions, a new study found that weather factors do not appear to be a risk factor for pain.

These data contribute to existing research into links observed between rheumatic diseases such as gout and cardiovascular disease among Indigenous North American populations.

Interactions with alcohol consumption were identified at ADH1B and MLXIPL for association with serum urate level and at ADH1B for association with hyperuricemia and gout